Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Satoshi DoteEiji ShiwakuEmiko KohnoRyohei FujiiKeiji MashimoNaomi MorimotoMasaki YoshinoNaoki OdairaHiroaki IkesueMasaki HirabatakeKatsuyuki TakahashiMasaya TakahashiMari TakagiSatoshi NishiumaKaori ItoAkane ShimatoShoji ItakuraYoshitaka TakahashiYutaka NegoroMina ShigemoriHiroyuki WatanabeDai HayasakaMasahiko NakaoMisaki TasakaEmi GotoNoriaki KataokaAyako YokomizoAyako KobayashiYoko NakataMafumi MiyakeYaeko HayashiYoshie YamamotoTaiki HirataKanako AzumaKatsuya MakiharaRino FukuiAkira TokutomeKeiji YagisawaShinji HondaYuji MeguroShota SuzukiDaisuke YamaguchiHitomi MiyataYuka Kobayashinull nullPublished in: International journal of clinical oncology (2023)
Sequential FOLFIRI plus RAM after BEV failure, especially within 55 days, may exacerbate proteinuria. Its escalated anti-VEGF toxicity may negatively impact the overall survival.